Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023584 | 1.00 | TSHR (0.59) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL1023299 | 0.99 | TSHR (0.57) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL9050997 | 0.99 | TSHR (0.57) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| Fumaric Acid SCHEMBL9051209 | 0.94 | TSHR (0.52) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| SCHEMBL8539574 | 0.91 | TSHR (0.59) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL30037316 | 0.90 | TSHR (0.57) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL9076705 | 0.90 | TSHR (0.57) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| Fumaric Acid SCHEMBL9052770 | 0.88 | POLB (0.52) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| Fumaric Acid SCHEMBL9051223 | 0.85 | TSHR (0.52) | TSHRMAPTLMNAMAPK1HSD17B10 | |
| SCHEMBL9050600 | 0.82 | KEAP1 (0.55) | TSHRMAPTLMNAMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2286817-A2 | Method of treating functional bowel disorders | Edusa Pharmaceuticals, Inc (US) | 2011-02-23 | — | — | EP | claimed |
| EP-0993829-B1 | TRANSDERMAL PREPARATION CONTAINING SEROTONIN RECEPTOR ANTAGONIST | HISAMITSU PHARMACEUTICAL CO (JP) | 2011-01-12 | — | — | EP | claimed |
| JP-2006522144-A | — | — | 2006-09-28 | — | — | JP | claimed |
| JP-2006516977-A | — | — | 2006-07-13 | — | — | JP | claimed |
| JP-2006516976-A | — | — | 2006-07-13 | — | — | JP | claimed |
| EP-1558081-A4 | METHOD OF TREATING FUNCTIONAL BOWEL DISORDERS | DYNOGEN PHARMACEUTICALS INC (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1567163-A4 | METHOD OF TREATING NAUSEA, VOMITING, RETCHING OR ANY COMBINATION THEREOF | DYNOGEN PHARMACEUTICALS INC (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1539181-A4 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050192270-A1 | Methods of decreasing intestinal motility | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | US | claimed |
| EP-1567163-A2 | METHOD OF TREATING NAUSEA, VOMITING, RETCHING OR ANY COMBINATION THEREOF | Dynogen Pharmaceuticals Inc. (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004062623-A2 | METHOD OF TREATING FUNCTIONAL BOWEL DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-20040147509-A1 | Method of treating functional bowel disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| WO-2004062624-A2 | METHOD OF TREATING NAUSEA, VOMITING, RETCHING OR ANY COMBINATION THEREOF | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-20040147510-A1 | Method of treating nausea, vomiting, retching or any combination thereof | DYNOGEN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | claimed |
| EP-1230921-A1 | Combination treatment for depression | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | claimed |
| EP-0381422-B1 | Tetrahydrobenzimidazole derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1996-10-23 | — | — | EP | claimed |
| US-5344927-A | 5-HT3 antagonist | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | claimed |
| EP-0381422-A1 | Tetrahydrobenzimidazole derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-08-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147509-A1 | Method of treating functional bowel disorders | HTR3B, HTR3A, HTR5A | TSHR 1998/4885MAPT 3639/4885LMNA 3254/4885 |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | HTR3A, HTR3E, HTR4 | TSHR 327/4885MAPT 3927/4885LMNA 3268/4885 |
| US-20040029972-A1 | Combination treatment for depression | HTR3A, HTR5A, HTR6 | TSHR 269/4885MAPT 2176/4885LMNA 2422/4885 |
| US-20040147510-A1 | Method of treating nausea, vomiting, retching or any combination thereof | HTR3B, HTR3A, NTSR2 | TSHR 541/4885MAPT 2975/4885LMNA 3938/4885 |
| US-20050192270-A1 | Methods of decreasing intestinal motility | HTR3B, HTR3A, HTR5A | TSHR 2267/4885MAPT 3592/4885LMNA 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.